|
CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication application
|
Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC) CStone plans to submit new indication applicat...
Full "IntellAsia: Resources" article
|
|